吗替麦考酚钠在葡萄膜炎免疫抑制治疗中的应用。

Mycophenolate sodium for immunosuppressive treatment in uveitis.

机构信息

Centre for Ophthalmology, University of Tübingen, Tübingen, Germany.

出版信息

Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):415-9. doi: 10.3109/09273940903137675.

DOI:10.3109/09273940903137675

PMID:20001262

Abstract

PURPOSE

To assess the efficacy and tolerability of mycophenolate sodium (MPS) in patients with uveitis.

METHODS

Retrospective analysis including uveitis patients treated with MPS (Myfortic) for at least 3 months duration. MPS was administered in a dose of 720 mg twice daily.

RESULTS

We analyzed 35 patients (65 affected eyes) with anterior (n = 5), intermediate (n = 23), posterior (n = 6), and panuveitis (n = 1). Previous treatment consisted of systemic corticosteroids in all patients and at least one immunomodulating agent in 15 patients. Mean duration of MPS therapy was calculated as 9.6 months (3-31 months). MPS was able to control intraocular inflammation without relapse in 30 patients (85.7%). Stabilization or improvement of visual acuity was achieved in 60 eyes (92.3%). Tolerability of MPS was good or moderate in 34 patients (97.1%).

CONCLUSIONS

MPS was demonstrated as an effective and well-tolerated immunosuppressive drug for different forms of uveitis.

摘要

目的

评估吗替麦考酚酯（MPS）治疗葡萄膜炎患者的疗效和耐受性。

方法

回顾性分析至少接受 MPS（霉酚酸酯）治疗 3 个月的葡萄膜炎患者。MPS 的剂量为每天两次 720mg。

结果

我们分析了 35 名（65 只患眼）前葡萄膜炎（n=5）、中间葡萄膜炎（n=23）、后葡萄膜炎（n=6）和全葡萄膜炎（n=1）患者。所有患者既往均接受全身皮质激素治疗，15 例患者至少接受过一种免疫调节剂治疗。MPS 治疗的平均持续时间为 9.6 个月（3-31 个月）。30 例（85.7%）患者的眼内炎症得到控制，无复发。60 只眼（92.3%）视力稳定或改善。34 例（97.1%）患者对 MPS 的耐受性良好或中度。